INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3201, 12731, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3202, 17249, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3203, 21222, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3204, 21800, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3205, 21801, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3206, 21803, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3207, 21804, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3208, 21805, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3209, 21806, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3210, 21808, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3211, 21809, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3212, 21811, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3213, 21812, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3214, 21815, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3215, 21816, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3216, 21821, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3217, 21822, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3218, 21824, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3219, 21827, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3220, 21829, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3221, 22271, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3222, 25301, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3223, 28382, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3224, 28676, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3225, 29789, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3226, 29790, 'Lidocaine (topical)', 'Kidney Diseases', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Lidocaine is primarily eliminated by the kidney.  Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties.   Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment.  Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated  doses in patients with compromised renal function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3227, 3338, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3228, 4646, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3229, 4648, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3230, 7294, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3231, 7296, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3232, 7297, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3233, 7299, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3234, 7308, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3235, 7311, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3236, 7312, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3237, 7317, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3238, 11847, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3239, 12731, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3240, 17249, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3241, 21222, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3242, 21800, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3243, 21801, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3244, 21803, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3245, 21804, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3246, 21805, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3247, 21806, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3248, 21808, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3249, 21809, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3250, 21811, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3251, 21812, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3252, 21815, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3253, 21816, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3254, 21821, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3255, 21822, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3256, 21824, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3257, 21827, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3258, 21829, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3259, 22271, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3260, 25301, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3261, 28382, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3262, 28676, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3263, 29789, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3264, 29790, 'Lidocaine (topical)', 'Seizures', 'Lidocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine.  Seizures can occur as a result of accumulation of active metabolites.  Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3265, 3338, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3266, 4646, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3267, 4648, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3268, 7294, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3269, 7296, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3270, 7297, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3271, 7299, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3272, 7308, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3273, 7311, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3274, 7312, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3275, 7317, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3276, 11847, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3277, 12731, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3278, 17249, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3279, 21222, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3280, 21800, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3281, 21801, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3282, 21803, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3283, 21804, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3284, 21805, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3285, 21806, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3286, 21808, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3287, 21809, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3288, 21811, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3289, 21812, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3290, 21815, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3291, 21816, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3292, 21821, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3293, 21822, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3294, 21824, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3295, 21827, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3296, 21829, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3297, 22271, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3298, 25301, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3299, 28382, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3300, 28676, 'Lidocaine', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', '', 'DDInter', 0);
